Surmodics

SRDX · NASDAQ

Price unavailable right now.

No price history for this range.

SRDX analyst rating

SellConsensus of 1 analyst over the last 12 months. 0% rate it a buy.

Strong buy0
Buy0
Hold0
Underperform1
Sell0

12-month price target · 3 analysts

Average $43.86

Low: $43.43
High: $45.15

Upgrades and downgrades

The latest rating actions, newest first

SRDX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Hit rate
Barrington Research	Nov 14, 2025	Downgrade	Market Perform → Underperform	44%

The case for and against

Updated Oct 19, 2025

Bull case

Surmodics Inc. is poised for substantial revenue growth due to its strategic investment in a whole-products solutions approach, which has led to the establishment of a direct sales force for its Pounce thrombectomy and Sublime radial access products. Despite increased operating expenses associated with these initiatives, the company's focus on enhancing its Medical Device segment, which includes advanced performance coating technologies and innovative medical devices, demonstrates its commitment to strengthening its market position. Overall, this proactive investment strategy, particularly within the domestic market, positions Surmodics favorably for future financial performance.

Bear case

Surmodics Inc. is facing significant challenges, primarily due to declining sales of its SurVeil drug-coated balloon, which has been compounded by reduced license fee revenue and lower sales to its distribution partner, Abbott. The company anticipates a larger-than-expected decrease in SurVeil sales for fiscal year 2025, which raises concerns about overall revenue growth. Additionally, the impact of these headwinds, including diminished coating royalty and license fee catch-up payments, is likely to further strain the financial performance of its Medical Device segment, which is crucial for the company’s revenue generation.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.